Manchester Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Manchester Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$916	Sell	16 -29	-64%	-$1.59K	﹤0.01%	1184
2026 Q1	$2.54K	Buy	45 +29	+181%	+$1.69K	﹤0.01%	980
2025 Q4	$951	Buy	16 +1	+7%	+$54	﹤0.01%	1145
2025 Q3	$813	Hold	15	–	–	﹤0.01%	1162
2025 Q2	$825	Sell	15 -18	-55%	-$1.06K	﹤0.01%	1080
2025 Q1	$2.33K	Sell	33 -1	-3%	-$67	﹤0.01%	987
2024 Q4	$2.23K	Buy	34 +3	+10%	+$201	﹤0.01%	977
2024 Q3	$2.18K	Buy	31 +10	+48%	+$836	﹤0.01%	987
2024 Q2	$1.73K	Buy	+21	New	+$1.75K	﹤0.01%	965
2024 Q1	–	Sell	-6	Closed	-$579	–	1038
2023 Q4	$579	Buy	+6	New	+$531	﹤0.01%	899
2021 Q1	–	Sell	-15	Closed	-$1K	–	657
2020 Q4	$1K	Buy	15 +12	+400%	+$951	﹤0.01%	635
2020 Q3	$0	Buy	+3	New	+$304	﹤0.01%	561

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Manchester Capital Management's BMRN Position: Q2 2026 in Review

Manchester Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 64% in Q2 2026, selling an estimated $1.59K and leaving 16 shares worth $916. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Manchester Capital Management first reported a position in BMRN in Q3 2020 and has held it in 12 quarters since. The position peaked at $2.54K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Manchester Capital Management held 16 shares of BioMarin Pharmaceuticals worth $916 as of Q2 2026.
Manchester Capital Management sold 29 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.59K.
BioMarin Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1184 holding.
Manchester Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
Manchester Capital Management's BioMarin Pharmaceuticals position peaked at $2.54K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.